Overview

Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need.

Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody that neutralizes CCL24 activity. In clinical and preclinical studies, CM-101 appears safe and has demonstrated the potential to treat multiple severe and life-threatening fibro-inflammatory diseases.

Chemomab has reported positive results from three clinical trials of CM-101 completed to date. A Phase 2 trial in the rare liver disease primary sclerosing cholangitis (PSC) has completed patient enrollment, with topline data expected midyear 2024.

Recent News
May 17, 2024

TEL AVIV, Israel ─ May 17, 2024 ─ Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory...

May 9, 2024

─On Track for Midyear 2024 Topline Data and Late 2024/Early 2025 Open Label Data Readouts from CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis (PSC), Following Early Completion of Patient...

May 8, 2024

TEL AVIV, Israel ─ May 8, 2024 ─ Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases...

May 2, 2024

TEL AVIV, Israel ─ May 2, 2024 ─ Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases...

All News

Stock Info
NASDAQCMMB
Events
Wednesday, May 22, 2024
7:30am - 9:30am EDT

Date: May 22, 2024
Time: 14:30-16:30 IDT
Format: Live panel presentation by CEO Adi Mor, PhD
Title: Pioneering Innovative Treatments for Inflammatory-Fibrotic Diseases
Information: Registration

Sunday, June 2, 2024 - Friday, June 7, 2024

Date: June 2 - 7, 2024
Format: Poster presentation: Attenuating liver fibrosis and inflammation: blocking CCL24 inhibits recruitment of hepatic stellate cells, monocytes and neutrophils and modulates hepatic stellate cell
Presenter: Prof. Amnon Peled, Hadassah University Hospital; Faculty of Medicine, Hebrew University
Information: 2024 Chemotactic Cytokines Conference GRC

All Events

Featured Presentations

Download

Chemomab Corporate Overview - May 2024